Newsroom

Sorted by: Latest

-

Alarm.com to Announce 2025 Fourth Quarter and Full Year Results on February 19, 2026

TYSONS, Va.--(BUSINESS WIRE)--Alarm.com to Announce 2025 Fourth Quarter and Full Year Results on February 19, 2026...
-

Chiplet Summit Announces Keynote Speakers

SANTA CLARA, Calif.--(BUSINESS WIRE)--Chiplet Summit, the biggest conference totally dedicated to chiplets, today announced the keynotes for its fourth annual event, February 17-19, at the Santa Clara Convention Center. “We have remarkable keynotes for the largest Chiplet Summit ever. They will highlight how chiplets are reshaping the semiconductor industry,” said Chuck Sobey, General Chair of Chiplet Summit. Wednesday Keynotes: Abhijeet Chakraborty, VP Engineering, Synopsys – Leads multi-die a...
-

Introducing Crosstie: Gain Life Rebrands to Expand Workflow Automation Across P&C Insurance Operations

BOSTON--(BUSINESS WIRE)--Gain Life, a provider of AI-powered workflow automation for property and casualty (P&C) insurance operations, today announced it has rebranded as “Crosstie,” a new name that reflects the company’s evolution and long-term vision as an integrated workflow automation platform for insurance operations. Founded at Harvard University’s Innovation Lab and live with customers since 2020, Crosstie has spent the past several years building and deploying a workflow automation...
-

Natera Submits Signatera™ CDx PMA to FDA

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for Signatera™ CDx for detection of molecular residual disease (MRD) in patients with muscle-invasive bladder cancer (MIBC) who may benefit from treatment with atezolizumab (Tecentriq®). This submission is supported by data from the randomized, double-blind, phase 3 IMvi...
-

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for t...
-

Ionic Mineral Technologies Secures Major SITLA Land Expansion at Silicon Ridge, Confirms Large-Scale Mineral System Continuity

PROVO, Utah--(BUSINESS WIRE)--Ionic Mineral Technologies Secures Major SITLA Land Expansion at Silicon Ridge, Confirms Large-Scale Mineral System Continuity...
-

As EV Buying Normalizes, VinFast Leans on Industry-Leading Warranties

MARKHAM, Ontario--(BUSINESS WIRE)--For most of his adult life, 40-year-old Marc Tremblay drove gasoline cars because that was simply what people did. He moved through a familiar sequence: a compact sedan, then an SUV as his family grew, along with occasional repairs and routine maintenance, big and small. So when he began thinking about an electric vehicle, it was not out of enthusiasm: he wanted to reduce fuel costs and simplify upkeep, but he was wary of diving headfirst into what seemed to h...
-

TNS Completes Acquisition of BT Radianz

RESTON, Va.--(BUSINESS WIRE)--Transaction Network Services (TNS) has completed its acquisition of BT’s Radianz business....
-

 Skip the Card this Valentine’s Day: Say It with Doughnuts! KRISPY KREME® Debuts All-New Valentine's Day Collection

CHARLOTTE, N.C.--(BUSINESS WIRE)--Roses are red, doughnuts are better, and Krispy Kreme’s® newest Valentine’s Day Collection is sweeter than a love letter! This Valentine's Day, skip the card and share a dozen doughnuts to say exactly what's in your heart. Available in a custom Valentine’s Day-themed dozen box beginning Tuesday, Feb. 3 through Valentine’s Day at participating Krispy Kreme shops throughout the U.S, Krispy Kreme’s Valentine’s Day Doughnut Collection includes four all-new doughnut...
-

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology highlighting the power of its ultrasensitive molecular residual disease (MRD) assay, NeXT Personal®, in monitoring immunotherapy response across a broad range of advanced cancers. The study, titled "Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer," wa...